Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

HC Wainwright reissued their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Thursday morning,Benzinga reports.

SRPT has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Mizuho increased their target price on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Oppenheimer reissued an “outperform” rating and set a $37.00 price target on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a report on Thursday, March 26th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $32.63.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $21.17 on Thursday. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. The firm has a market cap of $2.22 billion, a P/E ratio of -2.51, a P/E/G ratio of 0.31 and a beta of 0.29. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $64.80. The stock’s 50 day simple moving average is $19.02 and its 200 day simple moving average is $20.40.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same period in the prior year, the company posted $1.90 earnings per share. The business’s revenue was down 32.7% on a year-over-year basis. As a group, equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SRPT. Kestra Advisory Services LLC bought a new position in Sarepta Therapeutics during the fourth quarter valued at about $25,000. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics during the third quarter valued at about $25,000. Ancora Advisors LLC boosted its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares in the last quarter. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics during the third quarter valued at about $33,000. Finally, Allworth Financial LP boosted its stake in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.